New study pits Clot-Removal devices against drugs for dangerous lung clots
NCT ID NCT06453876
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial will test three ways to treat intermediate high-risk pulmonary embolism (a serious blood clot in the lungs). The study compares two catheter-based procedures (mechanical clot removal or low-dose clot-busting drug) with standard blood-thinning heparin. About 210 adults with recent symptoms will be enrolled. The goal is to see which method reduces clot burden most effectively within 48-96 hours.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Heparin, Alteplase, and catheter-based devices (AlphaVAC, FlowTriever, EKOS)
What this could lead to
If successful, this trial could identify the best approach to quickly reduce blood clots in the lungs, potentially improving recovery and reducing complications for people with serious pulmonary embolism.
What could go wrong
This is a phase 3 trial, but results may not apply to all patients. Bleeding risks exist with all treatments, and the study is relatively small (210 participants).
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY EMBOLISM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Copenhagen University Hospital Rigshospitalet
Copenhagen, DK2100, Denmark
-
Odense University Hospital
Odense, 5000, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••